A Prospective Open‐Label Observational Study of a Buffered Soluble 70 mg Alendronate Effervescent Tablet on Upper Gastrointestinal Safety and Medication Errors: The GastroPASS Study

Upper gastrointestinal (GI) side effects are a main reason for discontinuing bisphosphonate treatment, an important therapeutic option for osteoporosis patients. Consequently, the development of novel formulations with improved tolerability is warranted. In this multicenter prospective, observationa...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JBMR Plus
Päätekijät: Minisola, Salvatore, Vargas, Antonio P, Letizia Mauro, Giulia, Bonet Madurga, Fernando, Adami, Giovanni, Black, Dennis M, Qizilbash, Nawab, Blanch‐Rubió, Josep
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley & Sons, Inc. 2021
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8260812/
https://ncbi.nlm.nih.gov/pubmed/34258506
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jbm4.10510
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia